KR101171295B1 - 직접 피코르나비랄-매개 종양 용해를 통한 피검체의 악성종양 치료방법 - Google Patents

직접 피코르나비랄-매개 종양 용해를 통한 피검체의 악성종양 치료방법 Download PDF

Info

Publication number
KR101171295B1
KR101171295B1 KR1020057011510A KR20057011510A KR101171295B1 KR 101171295 B1 KR101171295 B1 KR 101171295B1 KR 1020057011510 A KR1020057011510 A KR 1020057011510A KR 20057011510 A KR20057011510 A KR 20057011510A KR 101171295 B1 KR101171295 B1 KR 101171295B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
cells
virus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057011510A
Other languages
English (en)
Korean (ko)
Other versions
KR20050115859A (ko
Inventor
대런 샤프렌
Original Assignee
비랄리틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비랄리틱스 리미티드 filed Critical 비랄리틱스 리미티드
Publication of KR20050115859A publication Critical patent/KR20050115859A/ko
Application granted granted Critical
Publication of KR101171295B1 publication Critical patent/KR101171295B1/ko
Assigned to 머크 샤프 앤드 돔 코포레이션 reassignment 머크 샤프 앤드 돔 코포레이션 권리의 전부이전등록 Assignors: 비랄리틱스 리미티드
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020057011510A 2002-12-18 2003-12-18 직접 피코르나비랄-매개 종양 용해를 통한 피검체의 악성종양 치료방법 Expired - Fee Related KR101171295B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002953436 2002-12-18
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
PCT/AU2003/001688 WO2004054613A1 (en) 2002-12-18 2003-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Publications (2)

Publication Number Publication Date
KR20050115859A KR20050115859A (ko) 2005-12-08
KR101171295B1 true KR101171295B1 (ko) 2012-08-07

Family

ID=30004521

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057011510A Expired - Fee Related KR101171295B1 (ko) 2002-12-18 2003-12-18 직접 피코르나비랄-매개 종양 용해를 통한 피검체의 악성종양 치료방법

Country Status (11)

Country Link
US (2) US7485292B2 (https=)
EP (1) EP1581257B1 (https=)
JP (2) JP2006517189A (https=)
KR (1) KR101171295B1 (https=)
CN (2) CN102166228B (https=)
AU (1) AU2002953436A0 (https=)
CA (1) CA2510227C (https=)
ES (1) ES2463678T3 (https=)
NZ (1) NZ541230A (https=)
WO (1) WO2004054613A1 (https=)
ZA (1) ZA200505389B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
CA2577692C (en) 2004-08-20 2014-05-06 Viralytics Limited Methods and compositions for treatment of hematologic cancers
WO2006074526A1 (en) * 2005-01-17 2006-07-20 Viralytics Limited Method and composition for treatment of neoplasms
EP2851078B1 (en) * 2012-04-19 2017-06-07 Kyushu University, National University Corporation Pharmaceutical composition
EP2826856B9 (en) 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
RU2682762C2 (ru) * 2013-11-27 2019-03-21 Общество С Ограниченной Ответственностью "Панацела Лабс" Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
EP4023233B1 (en) 2016-09-27 2026-01-07 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
EP3880812A4 (en) * 2018-11-13 2022-09-07 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037866A1 (en) 1999-11-25 2001-05-31 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113421A (en) * 1978-02-24 1979-09-05 Fumiaki Taguchi Large scale cultivation of virus
US5585254A (en) * 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
JPH04504361A (ja) 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1993000442A1 (en) * 1991-06-24 1993-01-07 The Research Foundation Of State University Of New York De novo cell-free synthesis of picornavirus
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE199568T1 (de) 1993-02-16 2001-03-15 Onyx Pharma Inc Cytopatische viren zur therapie und prophylaxe der neoplasie
EP2009119A1 (en) 1993-04-30 2008-12-31 Wellstat Biologics Corporation Compositions for treating cancer using viruses
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
CA2323067A1 (en) 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
DE60039730D1 (de) 1999-02-05 2008-09-11 Arch Dev Corp Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
JP2003530301A (ja) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
NZ517573A (en) 1999-09-17 2004-02-27 Pro Virus Inc Sequences of the oncolytic virus strain vesicular stromatitis virus (VSV)
EP1955703A1 (en) 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
EP1286678A2 (en) 2000-06-01 2003-03-05 Sloan-Kettering Institute For Cancer Research Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
JP2004519431A (ja) 2000-12-01 2004-07-02 ユニバーシティ・オブ・オタワ 腫瘍溶解性ウイルス
AU2002318104A1 (en) * 2001-01-05 2002-11-25 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
WO2002087625A1 (en) 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
US7264814B2 (en) 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
EP1385466B1 (en) 2001-05-11 2011-03-09 Wellstat Biologics Corporation Oncolytic virus therapy
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
EP1409653A4 (en) 2001-07-23 2006-05-03 Onyx Pharma Inc IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
AU2003216502B2 (en) 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
EP1499332A4 (en) 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
DE03722131T1 (de) 2002-05-09 2005-09-15 Oncolytics Biotech, Inc., Calgary Methode zur schmerzbekämpfung mit onkolytischen viren
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
US20070036758A1 (en) 2003-07-08 2007-02-15 Bertram Jacobs Mutants of vaccinia virus as oncolytic agents
WO2005030139A2 (en) 2003-09-26 2005-04-07 Novartis Ag Seneca valley virus based compositions and methods for treating disease
AU2005221725B2 (en) 2004-03-11 2010-06-24 Viralytics Limited Modified oncolytic viruses
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8080240B2 (en) 2004-10-21 2011-12-20 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037866A1 (en) 1999-11-25 2001-05-31 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EKSP Onkol. Vol. 11(5), pages 43-48 (1989)

Also Published As

Publication number Publication date
NZ541230A (en) 2008-04-30
CN1784242A (zh) 2006-06-07
CA2510227A1 (en) 2004-07-01
CA2510227C (en) 2015-03-31
US20100062020A1 (en) 2010-03-11
CN102166228A (zh) 2011-08-31
KR20050115859A (ko) 2005-12-08
ZA200505389B (en) 2006-09-27
US20060134778A1 (en) 2006-06-22
EP1581257A1 (en) 2005-10-05
AU2002953436A0 (en) 2003-01-09
CN1784242B (zh) 2011-06-08
JP2012046489A (ja) 2012-03-08
HK1157657A1 (en) 2012-07-06
ES2463678T3 (es) 2014-05-28
US7485292B2 (en) 2009-02-03
EP1581257A4 (en) 2007-10-17
WO2004054613A1 (en) 2004-07-01
JP2006517189A (ja) 2006-07-20
EP1581257B1 (en) 2014-04-30
CN102166228B (zh) 2014-02-19
HK1082194A1 (en) 2006-06-02

Similar Documents

Publication Publication Date Title
US20100062020A1 (en) Method of Treating a Malignancy in a Subject Via Direct Picornaviral-Mediated Oncolysis
US8722036B2 (en) Methods for treating malignancies using coxsackieviruses
Shafren et al. Oncolysis of human ovarian cancers by echovirus type 1
KR20060131975A (ko) 변형된 종양 용해 바이러스
CN101132798B (zh) 核酸分子在制备用于治疗黑色素瘤的药物中的应用及其组合物
AU2003287773B2 (en) A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
HK1157657B (en) A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
HK1082194B (en) Composition comprising echovirus ev1 and its use
AU770517B2 (en) A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2015230743A1 (en) A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
HK1157654A (en) Method and composition for treatment of neoplasms
HK1110802B (en) Use of nucleic acids in the preparation of a medicament for treating melanoma and the composition thereof
AU2006206053A1 (en) Method and composition for treatment of neoplasms

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160630

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170704

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210801

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210801